Opus acquires two compounds for inherited retinal diseases 02-Jan-2023 By Jane Byrne Last week saw Opus Genetics announce it had acquired the rights to two preclinical-stage adeno-associated virus (AAV)-based gene therapy product candidates for inherited retinal diseases (IRDs) from Iveric Bio.